Andere Sprachen Merck & Co., Inc.

Aktien

A0YD8Q

US58933Y1055

MRK

Pharmazeutika

Markt geschlossen - Nyse Andere Börsenplätze 22:00:02 12.01.2026			% 5 Tage	Veränd. 1. Jan.
109.19 ^USD	-1.21%		+1.63%	+3.73%

02:50	Merck & Co., Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 04:30 PM
02:00	Merck sieht neue Wachstumschancen und erwartet bis Mitte der 2030er Jahre einen Umsatz von 70 Milliarden Dollar	RE

Andere Sprachen

02:00	Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s
12.01.	Moderna expects $1.9 billion in sales, trims costs forecast for 2025
09.01.	Sector Update: Health Care Stocks Decline Late Afternoon
09.01.	Sector Update: Health Care Stocks Mixed Friday Afternoon
09.01.	Sector Update: Health Care
09.01.	Top Midday Stories: December Jobs Data Undershoots Expectations; Meta Signs Nuclear Deals
09.01.	Wall Street Gains Momentum Amid Jobs Report as US Equity Futures Edge Higher Pre-Bell
09.01.	Meta Platforms : Merck, General Motors, Eli Lilly... les valeurs à suivre aujourd'hui à Wall Street
09.01.	Merck reportedly consiering a major acquisition (Revolution Medicines)
09.01.	Merck envisagerait une grosse acquisition (Revolution Medicines)
09.01.	Merck Reportedly in Talks to Buy Revolution in Up to $32 Billion Deal
09.01.	AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty
09.01.	Merck & Co. in Talks to Acquire Revolution Medicines
08.01.	Price tag of $28bn to $32bn was being discussed as part of Merck-Revolution Medicines deal - FT
08.01.	Merck in talks to buy biotech Revolution in up to $32 billion deal, FT reports
08.01.	Merck in talks to buy biotech Revolution Medicines, Financial Times reports
08.01.	Merck in talks to buy cancer drugmaker Revolution Medicines-FT
08.01.	Merck Shares Rise After Wolfe Research Upgrade
08.01.	Independent expert group to review HPV vaccine evidence after US recommendation change
08.01.	USA-Les valeurs à suivre à Wall Street (actualisé)
07.01.	Vaxxas appoints former Merck global vaccines president David Peacock as CEO
07.01.	Merck lance un essai clinique de phase 3 dans le NSCLC
07.01.	Merck finalise son OPA sur Cidara Therapeutics
07.01.	Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib in Combination with KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph) in Certain Patients with Advanced NSCLC
07.01.	Merck Begins Phase 3 Trial of Calderasib With Keytruda QLEX in Non-Small Cell Lung Cancer

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen MarketScreener Artikel MarketScreener Analysen Trading-Ideen

Filter

Schlagzeilen

Merck übernimmt Verona Pharma für rund 10 Milliarden US-Dollar

Am 09. Juli 2025 um 18:30 Uhr